MFW
CCCC icon

Meristem Family Wealth’s C4 Therapeutics CCCC Stock Holding History

Meristem Family Wealth’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,000
Closed -$268K – 401
2021
Q3 		$268K Hold
6,000
– – 0.03% 337
2021
Q2 		$227K Buy
+6,000
New +$215K 0.04% 288

Other funds holding CCCC

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Meristem Family Wealth's CCCC Position: Q4 2021 in Review

Meristem Family Wealth sold out of C4 Therapeutics (CCCC) in Q4 2021, closing a stake of 6,000 shares — an estimated $268K sold.

Meristem Family Wealth first reported a position in CCCC in Q2 2021 and held it in 2 quarters. The position peaked at $268K in Q3 2021. 119 funds tracked by Wall St. Rank hold CCCC as of Q4 2021.

  • Meristem Family Wealth reported no remaining C4 Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Meristem Family Wealth sold 6,000 C4 Therapeutics shares in Q4 2021, an estimated $268K.
  • Meristem Family Wealth first reported a position in C4 Therapeutics in Q2 2021 and held it in 2 quarters.
  • Meristem Family Wealth's C4 Therapeutics position peaked at $268K in Q3 2021.
  • 119 funds tracked by Wall St. Rank held C4 Therapeutics as of Q4 2021.

Based on Meristem Family Wealth's 13F filing for Q4 2021, filed 10 Feb 2022.